AN INSIGHTFUL session on the future of lung transplantation presented at this year’s European Respiratory Society (ERS) ...

GSK is pumping £50 million (about $65 million) into a five-year collaboration with the University of Cambridge and Cambridge ...

The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy ...

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. | ...

IPF is a chronic, progressive lung disease marked by lung tissue thickening and scarring, leading to reduced lung function. It is a specific type of interstitial lung disease, which includes various ...

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

Columnist Charlene Marshall was confused when her latest pulmonary function test results didn't seem to reflect how she was feeling.

Emily Pink, 21, has cystic fibrosis, a rare genetic disorder that causes a build-up of sticky mucus in her lungs and ...

Structure Therapeutics has the potential to have a best-in-class GLP-1 agonist drug for treatment of patients with obesity. Learn more on GPCR stock here.

Lipid nanoparticles deliver CRISPR tools directly to lung stem cells, offering new therapeutic avenues for treating genetic ...

On a sunny and crisp fall day in Montgomery County, Arturo "Hito" Bazan remembers his darkest days. "Nothing really matters when you can't breathe. When you can't breathe, the world stops," Bazan told ...

The final patient completing our pivotal F351 Phase 3 trial marks an important milestone for Gyre and our development pipeline. We are grateful to the patients, researchers, trial investigators, and ...